These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23237838)

  • 21. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
    Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
    Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
    Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
    Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors.
    Kuo GH; Deangelis A; Emanuel S; Wang A; Zhang Y; Connolly PJ; Chen X; Gruninger RH; Rugg C; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
    J Med Chem; 2005 Jul; 48(14):4535-46. PubMed ID: 15999992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and biological evaluation of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors.
    Liu Z; Wang R; Guo R; Hu J; Li R; Zhao Y; Gong P
    Bioorg Med Chem; 2014 Jul; 22(14):3642-53. PubMed ID: 24882675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5.
    Watanabe N; Adachi H; Takase Y; Ozaki H; Matsukura M; Miyazaki K; Ishibashi K; Ishihara H; Kodama K; Nishino M; Kakiki M; Kabasawa Y
    J Med Chem; 2000 Jun; 43(13):2523-9. PubMed ID: 10891111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.
    Yu W; Xiao H; Lin J; Li C
    J Med Chem; 2013 Jun; 56(11):4402-12. PubMed ID: 23651330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and Biological Evaluation of New Phthalazinone Derivatives as Anti-Inflammatory and Anti-Proliferative Agents.
    Hameed AD; Ovais S; Yaseen R; Rathore P; Samim M; Singh S; Sharma K; Akhtar M; Javed K
    Arch Pharm (Weinheim); 2016 Feb; 349(2):150-9. PubMed ID: 26725221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological evaluation of some novel resveratrol amide derivatives as potential anti-tumor agents.
    Yao RS; Lu XQ; Guan QX; Zheng L; Lu X; Ruan BF
    Eur J Med Chem; 2013 Apr; 62():222-31. PubMed ID: 23353741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
    Menear KA; Adcock C; Boulter R; Cockcroft XL; Copsey L; Cranston A; Dillon KJ; Drzewiecki J; Garman S; Gomez S; Javaid H; Kerrigan F; Knights C; Lau A; Loh VM; Matthews IT; Moore S; O'Connor MJ; Smith GC; Martin NM
    J Med Chem; 2008 Oct; 51(20):6581-91. PubMed ID: 18800822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
    Kuo GH; Prouty C; Wang A; Emanuel S; Deangelis A; Zhang Y; Song F; Beall L; Connolly PJ; Karnachi P; Chen X; Gruninger RH; Sechler J; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
    J Med Chem; 2005 Jul; 48(15):4892-909. PubMed ID: 16033269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
    Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
    Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.
    Lin S; Zhang L; Zhang X; Yu Z; Huang X; Xu J; Liu Y; Chen L; Wu L
    Bioorg Med Chem; 2020 May; 28(9):115434. PubMed ID: 32222339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and potential anti-inflammatory activity of some tetrahydrophthalazinones.
    Gouault N; Pinel B; Cupif JF; Depince A; Martin-Chouly CA; Belleguic C; David M
    J Enzyme Inhib Med Chem; 2004 Dec; 19(6):475-80. PubMed ID: 15662951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3-[(6-Arylamino)pyridazinylamino]benzoic acids: design, synthesis and in vitro evaluation of anticancer activity.
    Abouzid KA; Khalil NA; Ahmed EM; Mohamed KO
    Arch Pharm Res; 2013 Jan; 36(1):41-50. PubMed ID: 23307426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Dragovich PS; Zhao G; Baumeister T; Bravo B; Giannetti AM; Ho YC; Hua R; Li G; Liang X; Ma X; O'Brien T; Oh A; Skelton NJ; Wang C; Wang W; Wang Y; Xiao Y; Yuen PW; Zak M; Zhao Q; Zheng X
    Bioorg Med Chem Lett; 2014 Feb; 24(3):954-62. PubMed ID: 24433859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New 1-phthalazinone Scaffold based Compounds: Design, Synthesis, Cytotoxicity and Protein Kinase Inhibition Activity.
    Abo-Elmagd NE; George RF; Ezzat MA; Arafa RK
    Mini Rev Med Chem; 2018; 18(20):1759-1774. PubMed ID: 30179133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, and molecular modeling of heterocyclic bioisostere as potent PDE4 inhibitors.
    Almatary AM; Elmorsy MA; El Husseiny WM; Selim KB; El-Sayed MA
    Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700403. PubMed ID: 29573453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl)phthalazine derivatives.
    Eldehna WM; Abou-Seri SM; El Kerdawy AM; Ayyad RR; Hamdy AM; Ghabbour HA; Ali MM; Abou El Ella DA
    Eur J Med Chem; 2016 May; 113():50-62. PubMed ID: 26922228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel tetrazole-based selective COX-2 inhibitors: Design, synthesis, anti-inflammatory activity, evaluation of PGE
    Labib MB; Fayez AM; El-Nahass ES; Awadallah M; Halim PA
    Bioorg Chem; 2020 Nov; 104():104308. PubMed ID: 33011534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel triazolophthalazine-hydrazone hybrids as potential PCAF inhibitors: Design, synthesis, in vitro anticancer evaluation, apoptosis, and molecular docking studies.
    Abulkhair HS; Turky A; Ghiaty A; Ahmed HEA; Bayoumi AH
    Bioorg Chem; 2020 Jul; 100():103899. PubMed ID: 32454390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.